Loading...
•
Dec 31, 2023
HilleVax Q4 2023 Earnings Report
Reported full year financial results and highlighted recent company progress.
Key Takeaways
HilleVax reported financial results for the year ended December 31, 2023. The company had $303.5 million in cash, cash equivalents and marketable securities as of December 31, 2023. Net loss for the fourth quarter 2023 was $37.0 million.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024.
Enrollment for NEST-IN1 study completed in Q2 2023
Cash, cash equivalents and marketable securities totaled $303.5 million as of December 31, 2023.
Sean McLoughlin appointed as Chief Operating Officer in Q1 2024.
HilleVax
HilleVax
Forward Guidance
HilleVax expects topline safety and clinical efficacy data from NEST-IN1 in mid-2024.